Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells

Breast Cancer Research

Volumn 8, Issue 2, 2006, Pages

  Yanochko, Gina M ^a   Eckhart, Walter ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; SERINE; SOMATOMEDIN C RECEPTOR; EPIDERMAL GROWTH FACTOR; INSULIN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER GROWTH; CANCER RISK; CELL POLARITY; CELL PROLIFERATION; CELL STRAIN HEK293; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOLOGY; DOWNSTREAM PROCESSING; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MONOLAYER CULTURE; MORPHOGENESIS; PHENOTYPE; POLARIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WILD TYPE; BREAST TUMOR; CELL CULTURE; CELL DIVISION; DRUG EFFECTS; GENE TRANSFER; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROVIRUS; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL POLARITY; CELL SURVIVAL; CELLS, CULTURED; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; GENE TRANSFER TECHNIQUES; HUMANS; INSULIN; MORPHOGENESIS; RECEPTOR, IGF TYPE 1; RETROVIRIDAE; SIGNAL TRANSDUCTION;

EID: 33746562548     PISSN: 1465542X     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1392     Document Type: Article

References (67)

1. Párrizas M, Saltiel AR, LeRoith D: Insulin-like growth factor I inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 1997, 272:154-161.
2. Burtscher I, Christofori G: The IGF/IGF-1 receptor signaling pathway as a potential target for cancer therapy. Drug Resist Update 1999, 2:3-8.
3. Bonnette SG, Hadsell DL: Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 2001, 142:4937-4945.
4. Ruan W, Kleinberg DL: Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 1999, 140:5075-5081.
5. Richards RG, Klotz DM, Walker MP, Diaugustine RP: Mammary gland branching morphogenesis is diminished in mice with a deficiency of insulin-like growth factor-I (IGF-I), but not in mice with a liver-specific deletion of IGF-I. Endocrinology 2004, 145:3106-3110.
6. Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, Rosen N: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 1990, 50:48-53.
7. Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, et al.: Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005, 65:3781-3787.
8. Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM: Targeted Expression of des(1-3) Human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 1996, 137:321-330.
9. Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laurcirica R, Rosen JM: Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene 2000, 19:889-898.
10. Yee D, Lee AV: Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000, 5:107-115.
11. Werner H, Karnieli E, Rauscher FJ III, LeRoith D: Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 1996, 93:8318-8323.
12. Werner H, Roberts CT Jr: The IGFI receptor gene: a molecular target for disrupted transcription factors. Genes Chromosomes Cancer 2003, 36:113-120.
13. Salatino M, Schillaci R, Proietti CJ, Carnevale R, Frahm I, Molinolo AA, Iribarren A, Charreau EH, Elizalde PV: Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves activation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone activity. Oncogene 2004, 23:5161-5174.
14. Dunn SE, Ehrlich M, Sharp NJH, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett JC: A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998, 58:3353-3361.
15. Goodwin PJ, Ennish M, Pritchard KI, Trudeau ME, Koo J, Hartwick W, Hoffman B, Hood N: Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat 2002, 74:65-76.
16. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A: Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000, 88:828-832.
17. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993, 53:3736-3740.
18. Resnik JL, Reichart DB, Huey K, Webster NJG, Seely BL: Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998, 58:1159-1164.
19. Berns EMJJ, Klijn JGM, van Staveren IL, Portengen H, Foekens JA: Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 1992, 52:1036-1039.
20. Kaleko M, Rutter WJ, Miller D: Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990, 10:464-473.
21. Jerome L, Shiry L, Leyland-Jones B: Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003, 10:561-578.
22. Sachdev D, Yee D: The IGF system and breast cancer. Endocr Relat Cancer 2001, 8:197-209.
23. Debnath J, Brugge JS: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005, 5:675-688.
24. Nelson CM, Bissell MJ: Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol 2005, 15:342-352.
25. Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM: Pleiotropic effects of FGFRI on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol 2005, 171:663-673.
26. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, Natesan S, Brugge JS: Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 2005, 171:1023-1024.
27. Arbet-Engels C, Janknecht R, Eckhart W: Role of focal adhesion kinase in MAP kinase activation by insulin-like growth factor-I or insulin. FEBS Lett 1999, 454:252-256.
28. Debnath J, Muthuswamy SK, Brugge JS: Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268.
29. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS: ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001, 3:785-792.
30. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS: The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 2002, 111:29-40.
31. Mills KR, Reginato M, Debnath J, Queenan B, Brugge JS: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc Natl Acad Sci USA 2004, 101:3438-3443.
32. Kato H, Faria TN, Stannard B, Roberts CT Jr, Le Roith D: Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. J Biol Chem 1993, 268:2655-2661.
33. Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, Stover C, Rutter WJ, Roth RA: Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem 1988, 263:11486-11492.
34. Kjeldsen T, Anderson AS, Wiberg FC, Rasmussen JS, Schaffer L, Balschmidt P, Moller KB, Moller NPH: The ligand specificities of the insulin receptor and the insulin-like growth factor I receptor reside in different regions of a common binding site. Proc Natl Acad Sci USA 1991, 88:4404-4408.
35. Wrobel CN, Debnath J, Lin E, Beausoleil S, Roussel MF, Brugge JS: Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture. J Cell Biol 2004, 165:263-273.
36. Zhu T, Starling-Emerald B, Zhang X, Lee K-O, Gluckman PD, Mertani HC, Lobie PE: Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res 2005, 65:317-324.
37. Brazil DP, Hemmings BA: Ten years of protein kinase B signaling: a hard Akt to follow. Trends Biochem Sci 2001, 26:657-664.
38. Nicholson KM, Anderson NG: The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 2002, 14:381-395.
39. Song G, Ouyang G, Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005, 9:59-71.
40. Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT: A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000, 60:3504-3513.
41. Navé BT, Ouwens DM, Withers DJ, Alessi DR, Shepherd PR: Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999, 344:427-431.
42. Chiang GG, Abraham RT: Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 2005, 280:25485-25490.
43. Holz MK, Blenis J: Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 2005, 280:26089-26093.
44. Liu H, Radisky DC, Wang F, Bissell MJ: Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol 2004, 164:603-612.
45. Reginato MJ, Mills KR, Becker EBE, Lynch DK, Bonni A, Muthuswamy SK, Brugge JS: Bim regulation of lumen formation in cultured mammary epithelial acini is targeted by oncogenes. Mol Cell Biol 2005, 25:4591-4601.
46. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al.: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998, 273:18623-18632.
47. Debnath J, Walker SJ, Brugge JS: Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J Cell Biol 2003, 163:315-326.
48. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham R: Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995, 270:815-822.
49. Polyak K: On the birth of breast cancer. Biochim Biophys Acta 2001, 1552:1-13.
50. Hanahan D, Weinberg RA: The hallmarks of Cancer. Cell 2000, 100:57-70.
51. Ruan W, Newman CB, Kleinberg DL: Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development. Proc Natl Acad Sci USA 1992, 89:10872-10876.
52. Kleinberg DL: Role of IGF-I in normal mammary development. Breast Cancer Res Treat 1998, 47:201-208.
53. Allan GJ, Tonner E, Barber MC, Travers MT, Shand JH, Vernon RG, Kelly PA, Binart N, Flint DJ: Growth hormone, acting in part through the insulin-like growth factor axis, rescues developmental, but not metabolic, activity in the mammary gland of mice expressing a single allele of the prolactin receptor. Endocrinology 2002, 143:4310-4319.
54. Guvakova MA, Surmacz E: Overexpressed IGF-I Receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res 1997, 231:149-162.
55. Weinsten IB: Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64.
56. Aoki K, Yoshida T., Matsumoto N, Ide H, Sugimura T, Terada M: Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol Carcinog 1997, 20:251-258.
57. Solit DB, Garraway CA, Pratilas CA, Sawaik A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, et al.: BRAF mutation predicts sensitivity to MEK inhibition. Nature 2005, 439:358-362.
58. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS: Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005, 65:10992-11000.
59. Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005, 8:179-183.
60. Harrington LS, Findlay GM, Lamb RF: Restraining PI3K: mTOR signaling goes back to the membrane. Trends Biochem Sci 2005, 30:35-42.
61. Sawyers CL: Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003, 4:343-348.
62. Bjornsti M-A, Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-348.
63. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human Breast Cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
64. Andrechek ER, White D, Muller WJ: Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth. Oncogene 2005, 24:932-937.
65. Osborne C, Wilson P, Tripathy D: Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 2004, 9:361-377.
66. Ingvarsson S: Molecular genetics of breast cancer progression. Semin Cancer Biol 1999, 9:277-288.
67. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G: Breast cancer. Lancet 2005, 365:1727-1741.